drugset / Trial / NCT06673368
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.
Timeline
- Start
- 2025-02-25
- Primary completion
- 2025-07-15
- Completion
- 2025-07-15
Outcome
Outcome not reported
Stopped (Enrollment): “Slow enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NRCT-101 | Unknown | — | — |
| Comparator | NRCT-202 | Unknown | — | — |